



ISSUE 29 | AUG 2026

REMAP-CAP

IN THIS ISSUE

- Welcome
- Core Protocol V4.0 Activation & Old Database Closure
- EU REMAP-CAP Website
- Regulatory Updates
- Influenza Antiviral Domain
- Welcome to the REMAP-CAP family!
- New Publications

Dear REMAP-CAP family,

After the hottest summer ever (at least in the Netherlands), these are exciting times for REMAP-CAP. We've published the results of the oseltamivir interventions in the Influenza Antiviral Domain, with full publication expected in the coming weeks. The results are important and will change treatment guidelines across the globe. See this newsletter for more information.

Additionally, now that summer is coming to an end, winter is approaching. Traditionally, winter brings more patients with acute respiratory illness (including influenza) to ICUs and hospital wards, providing a great opportunity to recruit patients to the trial.

We will discuss this, new domains, collaborations, and other aspects of REMAP-CAP relevant to Europe during an EU RMC face-to-face meeting in Lisbon. We'll keep you updated! Lastly, we're organizing a "Better Methods" course for our collaborators, which we highly recommend.

Enjoy reading this newsletter!

Lennie

Core Protocol V4.0 Activation & Old Database Closure

Over the last months, we were able to transition the majority of participating sites to Core Protocol V4.0 and the new database, with a few sites pending their transition. Participating sites that have not completed the transition by **31 August 2026** will not be able to enroll participants until they have transitioned to the new database linked to Protocol V4.0.

Of note: **Spain** was the first country to have completed the full transition! Thank you to all study teams for their coordination and support.

Following the transition deadline closure of the eligibility module, additional information will be shared regarding the data cleaning activities required for the old database for which we expect full closure in Q2 2027. Further guidance will be provided directly to sites

EU REMAP-CAP Website

We are pleased to share that the REMAP-CAP website is now back online and fully operational. Visit www.remapcap.eu to access live EU enrolment data, study protocols and essential study documentation, as well as our latest newsletters, publications, and other trial updates.

Top 3 recruiting sites since April 1st 2026

1. Centre Hospitalier de Dieppe (FR)
2. Tallaght University Hospital (IE)
3. Chesterfield Royal Hospital (UK)

Are you an early-career researcher working in clinical microbiology and infectious diseases using epidemiological and statistical methods?

Ecraid and ESCMID are organising the 'Better Methods for Clinical Studies in Infectious Diseases and Clinical Microbiology' course in Verona, Italy.

This programme bridges advanced theory with hands-on project mentorship. Gain critical insights into Target Trial Emulation, predictive AI methodologies, pragmatic trials, causal models, or how to optimally report your study for high-impact journals. The course offers a rare opportunity to have your active projects reviewed by leading experts in infectious disease research. [Read more](#)

Regulatory Updates

We successfully submitted **Substantial Modification (SM) 06** on **20 July 2026**. We would like to thank everyone who helped to coordinate and prepare the required documentation. This update includes several changes to the study documentation, including updates to the Core Protocol (update to V4.1), EU RSA, SmPCs and country-specific ICFs.

Modifications include revised wording for the Influenza Antiviral Domain, additional explanations regarding the questionnaires, and alignment with **ICH GCP E6(R3)** terminology. Several EU RSA country annexes and site-specific updates were submitted as well. Once SM-06 is approved, we will share relevant documents and details. Recently, also the **Annual Safety Report** was approved in CTIS and the version 10.1 has been shared with all EU sites for filing.

Ecraid x ESCMID Postgraduate course

Better methods for clinical studies in infectious diseases and clinical microbiology

6-8 October 2026
Verona, Italy

REGISTER TODAY



Influenza Antiviral Domain

In April the ITSC had decided to permanently close all oseltamivir-containing interventions in the **Severe State**.

UMC Utrecht, as Sponsor in the European region, will continue offering all six interventions of the Influenza Antiviral Domain to interested participating sites for the **Moderate State**. In the European region, recruitment remains open in the Severe State for Baloxavir versus no antiviral, and all interventions remain open in the Moderate illness severity state. If your site would like to participate in one of the open interventions, please reach out to your study team.

Welcome to the REMAP-CAP family!

In the Netherlands, we are adding sites in collaboration with RCCNet (Research Collaboration in Critical Care in the Netherlands). We welcome four new sites: **Medisch Spectrum Twente, St Antonius Ziekenhuis, ZGT Almelo and Jeroen Bosch Ziekenhuis!**

New Publications

Since our last newsletter, these papers have been published by the REMAP-CAP Investigators.

[Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial](#)

In a REMAP-CAP trial of 1,255 critically ill COVID-19 patients, intermediate-dose heparin did not improve survival or reduce need for organ support compared with standard low-dose thromboprophylaxis. The full article is available [here](#).

[Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19](#)

In the REMAP-CAP randomized trial, ivermectin did not improve organ support-free days or survival in hospitalized COVID-19 patients, whether critically ill or not. The study concluded ivermectin is unlikely to provide meaningful clinical benefit. The full article is available [here](#).

By winter, we expect one in three Dutch ICUs to participate in the trial - an amazing achievement for RCCNet and REMAP-CAP.

[Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial:](#)

A randomized trial of 442 critically ill influenza patients found that 5 or 10 days of oseltamivir did not improve outcomes and was associated with higher 90-day mortality ($\approx 19\%$ vs 14% without antivirals). Researchers concluded routine use in this population should be reconsidered. The preprint is available [here](#) and the FAQ addressed [here](#).

Save the date!

Ecraid Foundation
Science Meeting 2027

2-3 February 2027

Verona, Italy

Join Europe's leading infectious diseases research community [ecraid](#)



Mark your agenda to connect directly with Europe's leading ID and AMR experts, partners, and decision makers. More information to follow.

For live EU region enrolment data click [here](#)

World

- [240 sites](#)
- [16,399 unique patients](#)
- [27,634 randomisations](#)

European
region

- [91 sites](#)
- [8,793 unique patients](#)
- [16,074 randomisations](#)

Let's connect



The ECRAID-Base project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 965313



UMC Utrecht

ecraid

ecraid
Base